ELMSFORD, N.Y., Aug. 27, 2019 /PRNewswire/
-- NanoVibronix, Inc., (NASDAQ: NAOV), a
medical device company that produces the PainShield®
surface acoustic wave (SAW) device, today announced significant
progress with a leading global consumer healthcare company,
Medisana, which has resulted in an initial Original Equipment
Manufacturing (OEM) purchase order. The Company will commence the
manufacture of a specialized product for Medisana based on its
PainShield® device called the PT-100. The product will
be sold directly and exclusively via Medisana.
Medisana is a 30-year-old leading specialist in the home health
care market that develops, markets and sells products worldwide in
the categories of Mobile Health, Health Control, Wellness, Therapy,
Healthy Home, Regeneration and Personal Care for health-conscious
consumers.
Brian Murphy, CEO of NanoVibronix
Inc. said, "This is an amazing milestone for NanoVibronix and we
are honored to be partnering with a formidable global leader like
Medisana. This contract is the result of two years of hard work by
both companies, and the culmination of many successful user-based
trials. We hope that it can lead to greater successes and future
collaboration and revenue over time."
Rafael Aviram, Vice President,
Marketing & Innovation of Medisana, added, "We at Medisana are
always looking to introduce cutting edge technology and innovation
into our product portfolio, and we are confident that the Medisana
PT 100 will be a very successful new member within our wide range
of solutions. We welcome NanoVibronix and look forward to a
prosperous cooperation together."
About NanoVibronix
NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New
York, with research and development in Nesher, Israel, which is focused on developing medical
devices utilizing its proprietary and patented low intensity
surface acoustic wave (SAW) technology. This technology allows for
the creation of low-frequency ultrasound waves that can be utilized
for a variety of medical applications, including the disruption of
biofilms and bacteria colonization, as well as providing pain
relief. The devices can be administered at home without the
assistance of medical professionals. The Company's primary products
include PainShield®, UroShield™ and
WoundShield™. Additional information about the Company
is available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains "forward-looking statements."
Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market acceptance of our existing
and new products or lengthy product delays in key markets; (ii)
negative or unreliable clinical trial results (iii) an inability to
secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi)
product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient
or inadequate reimbursement by governmental and other third party
payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our
products, which may not be successful, (x) legislative or
regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for
certain product components, (xii) the fact that we will need to
raise additional capital to meet our business requirements in the
future and that such capital may not be available, or may be
costly, dilutive or difficult to obtain and (xiii) the fact that we
conduct business in multiple foreign jurisdictions, exposing us to
foreign currency exchange rate fluctuations, logistical and
communications challenges, burdens and costs of compliance with
foreign laws and political and economic instability in each
jurisdiction. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company's filings with the
Securities and Exchange Commission (SEC), including the Company's
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC's web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
Investor Contacts:
Nanovibronix Inc
bmurphy@nanovibronix.com
(630) 338-5022
Or:
Brett Maas, Managing Principal,
Hayden IR, LLC
brett@haydenir.com
(646) 536-7331
View original
content:http://www.prnewswire.com/news-releases/nanovibronix-reports-significant-progress-with-a-leading-global-consumer-healthcare-company-300907306.html
SOURCE NanoVibronix, Inc.